Obesity is further often characterized by lower circulating levels of adiponectin, a hepatoprotective insulin-sensitizing adipokine with anti-inflammatory and anti-fibrotic effects [13], which has been described as a biomarker of MASLD disease severity [14]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.